Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1glp-1opioidsgastrointestinaldrug interaction

Clinicians Examine GI Risk From GLP-1 and Opioid Combination

Diabetes In Control reviews whether co-prescribing opioids with GLP-1 receptor agonists raises gastrointestinal adverse event risk.

MH
By Maren Holt · Senior Reporter, GLP-1
Sep 16 14:21 ETSource: Diabetes In Control

The wire

  1. 01Report examines potential interaction between GLP-1 drugs and opioids on GI risk.
  2. 02Both drug classes slow gastric motility, a concern for widely co-prescribed patients.
  3. 03Magnitude of added risk and clinical guidance remain unresolved.

From the source

GLP-1 and Opioid Interaction: Is GI Risk Higher?

Read at news.google.com
Source URL https://news.google.com/rss/articles/CBMidkFVX3lxTE5IR2dFN0w2NndNZUwyMjdYb2R6bzZ5ejZTTDR1V2xTYTIyLXpIS096T0JZRnZGdGlvX2h1NnRaQWpwbDNheUhIdUlNVUg4azJKbDhSTWVSYnB6S05aT18wZW1TaktacEdVakN2dnZRSHN6T0NmUnc?oc=5